Cited by 2,323COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchRespiratory viral infections research

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Open access

Hammond, Jennifer, Leister-Tebbe, Heidi, Gardner, Annie, Abreu, Paula, Bao, Weihang, Wisemandle, Wayne, Baniecki, MaryLynn, Hendrick, Victoria M., Damle, Bharat, Simón-Campos, Abraham, Pypstra, Rienk, Rusnak, James M.·2022·New England Journal of Medicine

DOI 10.1056/nejmoa2118542PMC PMC8908851

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUNDNirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (M pro ) inhibitor with potent pan-human-coronavirus activity in vitro. METHODSWe conducted a phase 2-3 double-blind, randomized, controlled trial in which symptomatic, unvaccinated, nonhospitalized adults at high risk for progression to severe coronavirus disease 2019 (Covid-19) were assigned in a 1:1 ratio to receive either 300 mg of nirmatrelvir plus 100 mg of ritonavir (a pharmacokinetic enhancer) or placebo every 12 hours for 5 days.Covid-19-related hospitalization or death from any cause through day 28, viral load, and safety were evaluated. RESULTSA total of 2246 patients underwent randomization; 1120 patients received nirmatrelvir plus ritonavir (nirmatrelvir group) and 1126 received placebo (placebo group).In the planned interim analysis of patients treated within 3 days after symptom onset (modified intention-to treat population, comprising 774 of the 1361 patients in the full analysis population), the incidence of Covid-19-related hospitalization or death by day 28 was lower in the nirmatrelvir group than in the placebo group by 6.32 percentage points (95% confidence interval [CI], -9.04 to -3.59; P<0.001; relative risk reduction, 89.1%); the incidence was 0.77% (3 of 389 patients) in the nirmatrelvir group, with 0 deaths, as compared with 7.01% (27 of 385 patients) in the placebo group, with 7 deaths.Efficacy was maintained in the final analysis involving the 1379 patients in the modified intention-to-treat population, with a difference of -5.81 percentage points (95% CI, -7.78 to -3.84; P<0.001; relative risk reduction, 88.9%).All 13 deaths occurred in the placebo group.The viral load was lower with nirmatrelvir plus ritonavir than with placebo at day 5 of treatment, with an adjusted mean difference of -0.868 log 10 copies per milliliter when treatment was initiated within 3 days after the onset of symptoms.The incidence of adverse events that emerged during the treatment period was similar in the two groups (any adverse event, 22.6% with nirmatrelvir plus ritonavir vs. 23.9% with placebo; serious adverse events, 1.6% vs. 6.6%; and adverse events leading to discontinuation of the drugs or placebo, 2.1% vs. 4.2%).Dysgeusia (5.6% vs. 0.3%) and diarrhea (3.1% vs. 1.6%) occurred more frequently with nirmatrelvir plus ritonavir than with placebo. CONCLUSIONSTreatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower than the risk with placebo, without evident safety concerns.(Supported by Pfizer; ClinicalTrials.govnumber, NCT04960202.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2118542

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., Barengo, N. C., Beaton, A. Z., Benjamin, E. J., Benziger, C. P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.010 · Cited by 11,449
Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants.
(2016) · The Lancet · doi:10.1016/s0140-6736(16)30054-x · Cited by 5,212
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis
Zheng, Z., Peng, F., Xu, B., Zhao, J., Liu, H., Peng, J., Li, Q., Jiang, C., Zhou, Y., Liu, S., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.04.021 · Cited by 2,074
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
Owen, D. R., Allerton, C. M. N., Anderson, A. S., Aschenbrenner, L., Avery, M., Berritt, S., Boras, B., Cardin, R. D., Carlo, A., Coffman, K. J., et al. (2021) · Science · doi:10.1126/science.abl4784 · Cited by 2,033

Show all 21 references

Sorted by citations

The evolution of SARS-CoV-2
Markov, P. V., Ghafari, M., Beer, M., Lythgoe, K., Simmonds, P., Stilianakis, N. I., & Katzourakis, A. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00878-2 · Cited by 1,179
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823
Therapeutic strategies for COVID-19: progress and lessons learned
Li, G., Hilgenfeld, R., Whitley, R. J., & Clercq, E. D. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00672-y · Cited by 710
Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients
Najjar‐Debbiny, R., Gronich, N., Weber, R., Khoury, J., Amar, M., Stein, N., Goldstein, L. H., & Saliba, W. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac443 · Cited by 537
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
Iketani, S., Mohri, H., Culbertson, B., Hong, S. J., Duan, Y., Luck, M. I., Annavajhala, M. K., Guo, Y., Sheng, Z., Uhlemann, A., et al. (2022) · Nature · doi:10.1038/s41586-022-05514-2 · Cited by 503
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
Arbel, R., Sagy, Y. W., Hoshen, M. B., Battat, E., Lavie, G., Sergienko, R., Friger, M. D., Waxman, J. G., Dagan, N., Balicer, R. D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204919 · Cited by 365
Association of Treatment With Nirmatrelvir and the Risk of Post–COVID-19 Condition
Xie, Y., Choi, T., & Al‐Aly, Z. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.0743 · Cited by 352
ZBP1-dependent inflammatory cell death, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy during coronavirus infection
Karki, R., Lee, S., Mall, R., Nagakannan, P., Wang, Y., Sharma, B. R., Malireddi, R. K. S., Yang, D., Trifkovic, S., Steele, J. A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo6294 · Cited by 349
Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir
Hu, Y., Lewandowski, E. M., Tan, H., Zhang, X., Morgan, R. T., Zhang, X., Jacobs, L. M. C., Butler, S. G., Gongora, M. V., Choy, J. S., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00538 · Cited by 348
Nirmatrelvir Plus Ritonavir: First Approval
Lamb, Y. N. (2022) · Drugs · doi:10.1007/s40265-022-01692-5 · Cited by 319
Preventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2
Xu, Z., Shi, D., Han, J.-B., Ling, Y., Jiang, X., Lu, X., Li, C., Gong, L., Ge, G., Zhang, Y., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01429-0 · Cited by 304
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study
Wong, C. K. H., Au, I. C. H., Lau, K. T. K., Lau, E. H. Y., Cowling, B. J., & Leung, G. M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01586-0 · Cited by 299
Acute graft-versus-host disease
Malard, F., Holler, E., Sandmaier, B. M., Huang, H., & Mohty, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00438-1 · Cited by 301
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2
Uraki, R., Kiso, M., Iida, S., Imai, M., Takashita, E., Kuroda, M., Halfmann, P., Loeber, S. J., Maemura, T., Yamayoshi, S., et al. (2022) · Nature · doi:10.1038/s41586-022-04856-1 · Cited by 281
Modeling transmission of SARS-CoV-2 Omicron in China
Cai, J., Deng, X., Yang, J., Sun, K., Liu, H., Chen, Z., Peng, C., Chen, X., Wu, Q., Zou, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01855-7 · Cited by 275
Recent advances in regenerative biomaterials
Cao, D., & Ding, J. (2022) · Regenerative Biomaterials · doi:10.1093/rb/rbac098 · Cited by 277
Recommendations for the Management of Drug–Drug Interactions Between the COVID ‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications
Marzolini, C., Kuritzkes, D. R., Marra, F., Boyle, A., Gibbons, S., Flexner, C. W., Pozniak, A., Boffito, M., Waters, L. J., Burger, D. M., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2646 · Cited by 273
Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study
Wong, C. K. H., Au, I. C. H., Lau, K. T. K., Lau, E. H. Y., Cowling, B. J., & Leung, G. M. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00507-2 · Cited by 269
The development of COVID-19 treatment
Yuan, Y., Jiao, B., Qu, L., Yang, D., & Liu, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125246 · Cited by 269
Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19.
Bramante, C. T., Huling, J. D., Tignanelli, C. J., Buse, J. B., Liebovitz, D. M., Nicklas, J. M., Cohen, K., Puskarich, M. A., Belani, H. K., Proper, J. L., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201662 · Cited by 242
VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19
Cao, Z., Gao, W., Bao, H., Feng, H., Mei, S., Chen, P., Gao, Y., Cui, Z., Zhang, Q., Meng, X., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208822 · Cited by 236
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors
Boby, M. L., Fearon, D., Ferla, M., Filep, M., Koekemoer, L., Robinson, M. C., Chodera, J. D., Lee, A. A., London, N., von Delft, A., et al. (2023) · Science · doi:10.1126/science.abo7201 · Cited by 238
Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system
Zhou, Y., Gammeltoft, K. A., Ryberg, L. A., Pham, L. V., Tjørnelund, H. D., Binderup, A., Hernandez, C. R. D., Fernandez-Antunez, C., Offersgaard, A., Fahnøe, U., et al. (2022) · Science Advances · doi:10.1126/sciadv.add7197 · Cited by 227
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial
Montgomery, H., Hobbs, R. F., Padilla, F., Arbetter, D. F., Templeton, A., Seegobin, S., Kim, K., Campos, J. A. S., Arends, R. H., Brodek, B. H., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00180-1 · Cited by 222
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
Bhimraj, A., Morgan, R. L., Shumaker, A. H., Baden, L. R., Cheng, V. C., Edwards, K. M., Gallagher, J. C., Gandhi, R. T., Muller, W. J., Nakamura, M., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac724 · Cited by 227
COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022
Havers, F. P., Pham, H., Taylor, C. A., WHITAKER, M. D., Patel, K., Anglin, O., Kambhampati, A. K., Milucky, J., Zell, E. R., Moline, H. L., et al. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.4299 · Cited by 200
Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir
Duan, Y., Zhou, H., Liu, X., Iketani, S., Lin, M.-M., Zhang, X., Bian, Q., Wang, H., Sun, H., Hong, S. J., et al. (2023) · Nature · doi:10.1038/s41586-023-06609-0 · Cited by 193
The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir
Jochmans, D., Liu, C., Donckers, K., Stoycheva, A. D., Boland, S., Stevens, S., Vita, C. D., Vanmechelen, B., Maes, P., Trüeb, B. S., et al. (2023) · mBio · doi:10.1128/mbio.02815-22 · Cited by 192
Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System: A Population-Based Cohort Study
Dryden-Peterson, S., Kim, A., Kim, A. Y., Caniglia, E. C., Lennes, I. T., Patel, R., Gainer, L., Dutton, L., Donahue, E., Gandhi, R. T., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2141 · Cited by 182
Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics
Leng, A., Shah, M. M., Ahmad, S. A., Premraj, L., Wildi, K. S., Bassi, G. L., Pardo, C. A., Choi, A., & Cho, S. (2023) · Cells · doi:10.3390/cells12050816 · Cited by 188
Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Hashemian, S. M. R., Sheida, A., Taghizadieh, M., Memar, M. Y., Hamblin, M. R., Baghi, H. B., Nahand, J. S., Asemi, Z., & Mirzaei, H. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114367 · Cited by 184
Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir
Singh, R. S. P., Toussi, S. S., Hackman, F., Chan, P. L., Rao, R. P., Allen, R., Eyck, L. V., Pawlak, S., Kadar, E. P., Clark, F., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2603 · Cited by 164
Therapeutic advances in COVID-19
Murakami, N., Hayden, R., Hills, T. E., Al-Samkari, H. T., Casey, J. D., Sorbo, L. D., Lawler, P. R., Sise, M. E., & Leaf, D. E. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00642-4 · Cited by 166
Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study
Mukae, H., Yotsuyanagi, H., Ohmagari, N., Doi, Y., Sakaguchi, H., Sonoyama, T., Ichihashi, G., Sanaki, T., Baba, K., Tsuge, Y., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac933 · Cited by 153
Rebound of SARS-CoV-2 Infection after Nirmatrelvir–Ritonavir Treatment
Charness, M. E., Gupta, K., Stack, G. E., Strymish, J. M., Adams, E., Lindy, D. C., Mohri, H., & Ho, D. D. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2206449 · Cited by 151
Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019
Ganatra, S., Dani, S. S., Ahmad, J., Kumar, A., Shah, J., Abraham, G. M., McQuillen, D. P., Wachter, R. M., & Sax, P. E. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac673 · Cited by 148
Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system
Lewnard, J. A., McLaughlin, J. M., Malden, D. E., Hong, V. X., Puzniak, L., Ackerson, B. K., Lewin, B. J., Kim, J. S., Shaw, S. F., Takhar, H. S., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00118-4 · Cited by 150
Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID‐19: A rapid review and meta‐analysis
Amani, B., & Amani, B. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28441 · Cited by 144
COVID-19 in patients with hematologic malignancy
Langerbeins, P., & Hallek, M. J. (2022) · Blood · doi:10.1182/blood.2021012251 · Cited by 143
Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study
Aggarwal, N. R., Molina, K. C., Beaty, L. E., Bennett, T. D., Carlson, N. E., Mayer, D. A., Peers, J. L., Russell, S., Wynia, M. K., & Ginde, A. A. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00011-7 · Cited by 139
The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID
Li, J., Zhou, Y., Ma, J., Zhang, Q., Shao, J., Liang, S., Yu, Y., Li, W., & Wang, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01640-z · Cited by 147
Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19
Hammond, J., Fountaine, R. J., Yunis, C., Fleishaker, D. L., Almas, M., Bao, W., Wisemandle, W., Baniecki, M. L., Hendrick, V. M., Kalfov, V., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309003 · Cited by 138
Self-citation
Paxlovid: Mechanism of Action, Synthesis, and In Silico Study
Marzi, M., Vakil, M. K., Bahmanyar, M., & Zarenezhad, E. (2022) · BioMed Research International · doi:10.1155/2022/7341493 · Cited by 137
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part
Mukae, H., Yotsuyanagi, H., Ohmagari, N., Doi, Y., Imamura, T., Sonoyama, T., Fukuhara, T., Ichihashi, G., Sanaki, T., Baba, K., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00697-22 · Cited by 137
Effectiveness of COVID-19 Treatment With Nirmatrelvir–Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes
Bajema, K. L., Berry, K., Streja, E., Rajeevan, N., Li, Y., Mutalik, P., Yan, L., Cunningham, F. E., Hynes, D. M., Rowneki, M., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-3565 · Cited by 134
The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations
Joyce, R., Hu, V. W., & Wang, J. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02951-6 · Cited by 133
SARS-CoV-2 in immunocompromised individuals
DeWolf, S., Laracy, J. C., Perales, M., Kamboj, M., van den Brink, M. R. M., & Vardhana, S. A. (2022) · Immunity · doi:10.1016/j.immuni.2022.09.006 · Cited by 140
Impact of COVID-19 on Cardiovascular Disease
Vosko, I., Zirlik, A., & Bugger, H. (2023) · Viruses · doi:10.3390/v15020508 · Cited by 138
The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?
Loos, N. H. C., Beijnen, J. H., & Schinkel, A. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179866 · Cited by 128
Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19
Yotsuyanagi, H., Ohmagari, N., Doi, Y., Yamato, M., Bắc, N. H., Cha, B. K., Imamura, T., Sonoyama, T., Ichihashi, G., Sanaki, T., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.54991 · Cited by 128
Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection
Geng, L. N., Bonilla, H. F., Hedlin, H., Jacobson, K. B., Tian, L., Jagannathan, P., Yang, P. C.-M., Subramanian, A. K., Liang, J. W., Shen, S., et al. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.2007 · Cited by 126
Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro
Hou, N., Shuai, L., Zhang, L., Xie, X., Tang, K., Zhu, Y., Yin, Y., Zhang, W., Tan, Q., Zhong, G., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.2c01359 · Cited by 122
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)
Cesaro, S., Ljungman, P. T., Mikulska, M., Hirsch, H. H., von Lilienfeld‐Toal, M., Cordonnier, C., Meylan, S., Mehra, V., Styczyński, J., Marchesi, F., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01578-1 · Cited by 119
Small molecules in the treatment of COVID-19
Lei, S., Chen, X., Wu, J., Duan, X., & Men, K. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01249-8 · Cited by 119
Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance
Ip, J. D., Chu, A. W., Chan, W.-M., Leung, R. C.-Y., Abdullah, S. M., Sun, Y., & To, K. K. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104559 · Cited by 117
Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control
Wang, S., Li, W., Wang, Z., Yang, W., Li, E., Xia, X., Yan, F., & Chiu, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01917-x · Cited by 124
Vaccines and therapeutics for immunocompromised patients with COVID-19
Shoham, S., Batista, C., Amor, Y. B., Ergönül, Ö., Hassanain, M. M., Hotez, P. J., Kang, G., Kim, J. H., Lall, B., Larson, H. J., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101965 · Cited by 116
Therapeutics for COVID-19
Toussi, S. S., Hammond, J., Gerstenberger, B. S., & Anderson, A. S. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01356-4 · Cited by 113
Self-citation
S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters
Sasaki, M., Tabata, K., Kishimoto, M., Itakura, Y., Kobayashi, H., Ariizumi, T., Uemura, K., Toba, S., Kusakabe, S., Maruyama, Y., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq4064 · Cited by 108
Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
Anderson, A. S., Caubel, P., & Rusnak, J. M. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2205944 · Cited by 105
Self-citation
Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19
Wai, A. K. C., Chan, C. Y., Cheung, A. W.-L., Wang, K., Chan, S. C. L., Lee, T. T.-L., Luk, L. Y. F., Yip, T. F., Ho, J. W. K., Tsui, O. W.-K., et al. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100602 · Cited by 105
Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study
Liu, J., Pan, X., Zhang, S., Li, M., Ma, K., Fan, C., Lv, Y., Guan, X., Yang, Y., Ye, X., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100694 · Cited by 105
Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19
Naggie, S., Boulware, D. R., Lindsell, C. J., Stewart, T. G., Gentile, N., Collins, S. P., McCarthy, M. W., Jayaweera, D. T., Castro, M., Sulkowski, M., et al. (2022) · JAMA · doi:10.1001/jama.2022.18590 · Cited by 102
Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 — United States, April–September 2022
Shah, M. M., Joyce, B., Plumb, I. D., Sahakian, S., Feldstein, L. R., Barkley, E., Paccione, M., Deckert, J., Sandmann, D., Gerhart, J. L., et al. (2022) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7148e2 · Cited by 102
FDA approved fluorine-containing drugs in 2023
Wang, Q., Bian, Y., Dhawan, G., Zhang, W., Sorochinsky, A. E., Makarem, A., Soloshonok, V. A., & Han, J. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.109780 · Cited by 102
Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies
Chung, Y.-S., Lam, C.-Y., Tan, P.-H., Tsang, H. F., & Wong, S. C. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158155 · Cited by 116
Population-based evaluation of the effectiveness of nirmatrelvir–ritonavir for reducing hospital admissions and mortality from COVID-19
Schwartz, K. L., Wang, J., Tadrous, M., Langford, B. J., Daneman, N., Leung, V., Gomes, T., Friedman, L., Daley, P., & Brown, K. A. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.221608 · Cited by 99
Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019 Patients (COVID-19)
Yip, T. C., Lui, G. C.-Y., Lai, M. S., Wong, V. W., Tse, Y. K., Ma, B. H.-M., Hui, E., Leung, M. K., Chan, H. L., Hui, D. S.-C., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac687 · Cited by 98
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19
Allerton, C. M. N., Arcari, J. T., Aschenbrenner, L. M., Avery, M., Bechle, B. M., Behzadi, M. A., Boras, B. W., Buzon, L. M., Cardin, R. D., Catlin, N. R., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02469 · Cited by 95
Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α
Mathian, A., Breillat, P., Dorgham, K., Bastard, P., Charre, C., Lhote, R., Quentric, P., Moyon, Q., Mariaggi, A., Mouries-Martin, S., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-222549 · Cited by 98
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Li, X., & Song, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115772 · Cited by 94
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
Schilling, W. H., Jittamala, P., Watson, J. A., Boyd, S., Luvira, V., Siripoon, T., Ngamprasertchai, T., Batty, E. M., Cruz, C. V., Callery, J. J., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00493-0 · Cited by 91
Oral antiviral treatments for COVID-19: opportunities and challenges
Rahmah, L., Abarikwu, S. O., Arero, A. G., Essouma, M., Jibril, A. T., Fal, A., Flisiak, R., Makuku, R., Marquez, L. P., Mohamed, K., et al. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00388-7 · Cited by 88
Cognitive dysfunction in post‐COVID‐19 condition: Mechanisms, management, and rehabilitation
Möller, M. C., Borg, K., Janson, C., Lerm, M., Normark, J., & Niward, K. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13720 · Cited by 93
COVID-19 drug discovery and treatment options
Chan, J. F., Yuan, S., Chu, H., Sridhar, S., & Yuen, K. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01036-y · Cited by 89
Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge
Radcliffe, C. V., Palacios, C. F., Azar, M. M., Cohen, E., & Malinis, M. F. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17098 · Cited by 85
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs
Bastard, P., Vazquez, S. E., Liu, J., Laurie, M. T., Wang, C., Gervais, A., Voyer, T. L., Bizien, L., Zamecnik, C. R., Philippot, Q., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abp8966 · Cited by 85
COVID-19 and liver disease
Dufour, J., Marjot, T., Becchetti, C., & Tilg, H. (2022) · Gut · doi:10.1136/gutjnl-2021-326792 · Cited by 89
Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)
Boucau, J., Uddin, R., Marino, C., Regan, J., Flynn, J. P., Choudhary, M. C., Chen, G., Stuckwisch, A. M., Mathews, J., Liew, M. Y., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac512 · Cited by 85
Thromboinflammation in long COVID—the elusive key to postinfection sequelae?
Nicolai, L., Kaiser, R. W. J., & Stark, K. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.04.039 · Cited by 87
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper
Marjot, T., Eberhardt, C. S., Boettler, T., Belli, L. S., Berenguer, M., Buti, M., Jalan, R., Mondelli, M. U., Moreau, R., Shouval, D., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.008 · Cited by 84
Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave
Lu, G., Zhang, Y., Zhang, H., Ai, J., He, L., Yuan, X., Bao, S., Chen, X., Wang, H., Cai, J., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2109517 · Cited by 84
Efficacy and safety of Paxlovid for COVID-19:a meta-analysis
Zheng, Q., Ma, P., Wang, M., Cheng, Y., Zhou, M., Ye, L., Feng, Z., & Zhang, C. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.09.027 · Cited by 84
2-Ethynylbenzaldehyde-Based, Lysine-Targeting Irreversible Covalent Inhibitors for Protein Kinases and Nonkinases
Chen, P., Tang, G., Zhu, C., Sun, J., Wang, X., Xiang, M., Huang, H., Wang, W., Li, L., Zhang, Z., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11595 · Cited by 86
Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment
Carlin, A. F., Clark, A. E., Chaillon, A., Garretson, A. F., Bray, W. A., Porrachia, M., Santos, A. T., Rana, T. M., & Smith, D. M. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac496 · Cited by 81
Retrosynthesis prediction using an end-to-end graph generative architecture for molecular graph editing
Zhong, W., Yang, Z., & Chen, C. Y. (2023) · Nature Communications · doi:10.1038/s41467-023-38851-5 · Cited by 91
Cardiovascular disease as part of Long COVID: a systematic review
Tsampasian, V., Bäck, M., Bernardi, M., Cavarretta, E., Dębski, M., Gati, S., Hansen, D., Kränkel, N., Koskinas, K. C., Niebauer, J., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae070 · Cited by 79
Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection
Deo, R., Choudhary, M. C., Moser, C., Ritz, J., Daar, E. S., Wohl, D. A., Greninger, A. L., Eron, J. J., Currier, J. S., Hughes, M. D., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2381 · Cited by 77
Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2
Hirotsu, Y., Kobayashi, H., Kakizaki, Y., Saito, A., Tsutsui, T., Kawaguchi, M., Shimamura, S., Hata, K., Hanawa, S., Toyama, J., et al. (2023) · Med · doi:10.1016/j.medj.2023.08.001 · Cited by 77
Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant
Zhou, H., Møhlenberg, M., Thakor, J. C., Tuli, H. S., Wang, P., Assaraf, Y. G., Dhama, K., & Jiang, S. (2022) · Clinical Microbiology Reviews · doi:10.1128/cmr.00014-22 · Cited by 78
Linear versus cubic regression models for analyzing generalized reverse degree based topological indices of certain latest corona treatment drug molecules
Arockiaraj, M., Greeni, A. B., & Kalaam, A. R. A. (2023) · International Journal of Quantum Chemistry · doi:10.1002/qua.27136 · Cited by 76
Synthetic Gene Circuits for Regulation of Next‐Generation Cell‐Based Therapeutics
Teixeira, A. P., & Fussenegger, M. (2023) · Advanced Science · doi:10.1002/advs.202309088 · Cited by 76
Pathophysiological, immunological, and inflammatory features of long COVID
Böhmwald, K., Diethelm‐Varela, B., Rodríguez‐Guilarte, L., Rivera, T., Riedel, C. A., González, P. A., & Kalergis, A. M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1341600 · Cited by 79
SARS-CoV-2 Virologic Rebound With Nirmatrelvir–Ritonavir Therapy
Edelstein, G. E., Boucau, J., Uddin, R., Marino, C., Liew, M. Y., Barry, M., Choudhary, M. C., Gilbert, R. F., Reynolds, Z., Li, Y., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m23-1756 · Cited by 74
Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents
Zagórska, A., Czopek, A., Fryc, M., & Jończyk, J. (2024) · Biomolecules · doi:10.3390/biom14070797 · Cited by 74
Viral proteases as therapeutic targets
Majerová, T., & Konvalinka, J. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101159 · Cited by 76
Association Between AZD7442 (Tixagevimab-Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Hospitalization, and Mortality
Kertes, J., David, S. S. B., Engel-Zohar, N., Rosen, K., Hemo, B., Kantor, A., Adler, L., Shamir-Stein, N., Reuveni, M. M., & Shahar, A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac625 · Cited by 72
Long COVID: Costs for the German economy and health care and pension system
Gandjour, A. (2023) · BMC Health Services Research · doi:10.1186/s12913-023-09601-6 · Cited by 72
Age-specific rate of severe and critical SARS-CoV-2 infections estimated with multi-country seroprevalence studies
Herrera, D., & Campos, G. D. L. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07262-0 · Cited by 78

Authors: Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Baniecki, M., Hendrick, V. M., Damle, B., Simón-Campos, A., Pypstra, R., & Rusnak, J. M.
Affiliations: Pfizer (United States) (US)
From Global Product Development, Pfizer, Collegeville, PA (J.H., H.L.-T.); Global Product Development (A.G.) and Early Clinical Development (M.L.B.), Pfizer, Cambridge, MA; Global Product Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global Product Development, Pfizer, Tampa, FL (J.M.R.).
Corresponding author: Hammond, Jennifer
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2022-04-14
Volume: 386
Issue: 15
Pages: 1397-1408
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2118542
PMC: PMC8908851
OpenAlex: W4212904481
Cited by: 2,323
References: 21
Citations by year: 2026: 186 · 2025: 319 · 2024: 517 · 2023: 769 · 2022: 525
FWCI: 261.43
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Pfizer
Topics: Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
Keywords: nirmatrelvir, COVID-19 pandemic, SARS-CoV-2, Mpro inhibitors, ritonavir, oral antiviral therapy, high-risk adults, non-hospitalized patients, viral load, unvaccinated patients, early treatment, SARS-CoV-2 variants, Omicron variant
MeSH terms: Viral Protease Inhibitors, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Administration, Oral, Adult, Antiviral Agents, Double-Blind Method, Drug Combinations, Hospitalization, Humans, Lactams, Leucine, Nitriles, Proline, Vaccination, Treatment Outcome, Disease Progression, Ritonavir, Viral Load

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks